MCID: PLM008
MIFTS: 17

Pulmonary Subvalvular Stenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Pulmonary Subvalvular Stenosis

MalaCards integrated aliases for Pulmonary Subvalvular Stenosis:

Name: Pulmonary Subvalvular Stenosis 12 42 14 69
Infundibular Pulmonic Stenosis, Congenital 12
Congenital Infundibular Stenosis 12
Pulmonary Infundibular Stenosis 12
Infundibular Pulmonic Stenosis 12
Subvalvular Pulmonic Stenosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8861
ICD10 33 Q24.3
ICD9CM 35 746.83
MeSH 42 D011662
NCIt 47 C34961
SNOMED-CT 64 204370002 3192005
UMLS 69 C0034084

Summaries for Pulmonary Subvalvular Stenosis

MalaCards based summary : Pulmonary Subvalvular Stenosis, also known as infundibular pulmonic stenosis, congenital, is related to pulmonic stenosis and subpulmonary stenosis. An important gene associated with Pulmonary Subvalvular Stenosis is CRELD1 (Cysteine Rich With EGF Like Domains 1). The drugs Diltiazem and Antihypertensive Agents have been mentioned in the context of this disorder. Affiliated tissues include heart.

Related Diseases for Pulmonary Subvalvular Stenosis

Diseases related to Pulmonary Subvalvular Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 pulmonic stenosis 10.5
2 subpulmonary stenosis 10.2
3 marfan syndrome 9.9
4 azoospermia 9.9
5 ventricular septal defect 9.9

Graphical network of the top 20 diseases related to Pulmonary Subvalvular Stenosis:



Diseases related to Pulmonary Subvalvular Stenosis

Symptoms & Phenotypes for Pulmonary Subvalvular Stenosis

Drugs & Therapeutics for Pulmonary Subvalvular Stenosis

Drugs for Pulmonary Subvalvular Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diltiazem Approved Phase 2, Phase 3 42399-41-7 39186
2 Antihypertensive Agents Phase 2, Phase 3
3 calcium channel blockers Phase 2, Phase 3
4 Calcium, Dietary Phase 2, Phase 3
5 Vasodilator Agents Phase 2, Phase 3
6
Ethanol Approved Phase 2 64-17-5 702
7
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
8
Dipyridamole Approved Phase 2 58-32-2 3108
9
Valsartan Approved, Investigational Phase 2 137862-53-4 60846
10
Pirfenidone Investigational Phase 2 53179-13-8 40632
11
Angiotensin II Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12 Anti-Infective Agents Phase 2
13 Anti-Infective Agents, Local Phase 2
14 Central Nervous System Depressants Phase 2
15 Analgesics Phase 2
16 Analgesics, Non-Narcotic Phase 2
17 Anti-Inflammatory Agents Phase 2
18 Anti-Inflammatory Agents, Non-Steroidal Phase 2
19 Antirheumatic Agents Phase 2
20 Peripheral Nervous System Agents Phase 2
21 Antifungal Agents Phase 2
22 Calcineurin Inhibitors Phase 2
23 Cyclosporins Phase 2
24 Dermatologic Agents Phase 2
25 Immunosuppressive Agents Phase 2
26 Angiotensin II Type 1 Receptor Blockers Phase 2
27 Angiotensin Receptor Antagonists Phase 2
28 Angiotensinogen Phase 2
29
Enalapril Approved, Vet_approved 75847-73-3 5362032 40466924
30
Enalaprilat Approved 76420-72-9 6917719
31
Losartan Approved 114798-26-4 3961
32 Cardiac Glycosides
33 Complement Factor I
34 Hormones
35 insulin
36 Insulin, Globin Zinc
37 Mitogens
38 Angiotensin-Converting Enzyme Inhibitors
39 Anti-Arrhythmia Agents
40 HIV Protease Inhibitors
41
protease inhibitors
42 diuretics
43 Tin Fluorides

Interventional clinical trials:

(show all 31)

id Name Status NCT ID Phase Drugs
1 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Completed NCT00319982 Phase 2, Phase 3 Diltiazem;Placebo
2 Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle Completed NCT00001960 Phase 2
3 Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study Completed NCT00035386 Phase 2
4 Pirfenidone to Treat Hypertrophic Cardiomyopathy Completed NCT00011076 Phase 2 Pirfenidone
5 Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM) Completed NCT00001965 Phase 2 Cyclosporine A
6 A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy Completed NCT00001894 Phase 2
7 Study of Blood Flow in Heart Muscle Completed NCT00001631 Phase 2
8 Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM Recruiting NCT01912534 Phase 2 Valsartan;Placebo
9 Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop... Completed NCT00001396 Phase 1
10 Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study Unknown status NCT02424994
11 Screening for Inherited Heart Disease Completed NCT00001746
12 The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy Completed NCT00074880
13 Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy Completed NCT00753233
14 Genetic Analysis of Familial Hypertrophic Cardiomyopathy Completed NCT00005251
15 Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy Completed NCT00001530
16 Family Studies of Inherited Heart Disease Completed NCT00001225
17 Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease Completed NCT00001881
18 Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts Completed NCT00001878
19 Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease Completed NCT00001632
20 Study of Muscle Abnormalities in Patients With Specific Genetic Mutations Completed NCT00001871
21 Long Term Effects of Enalapril and Losartan on Genetic Heart Disease Completed NCT00001534 Losartan
22 Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers Completed NCT00001459
23 Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy Completed NCT01631006
24 Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers Completed NCT00253682
25 Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy Completed NCT00354328
26 Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures Completed NCT00692991
27 Stress Echo 2020 - The International Stress Echo Study Recruiting NCT03049995
28 An Integrative-"Omics" Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Recruiting NCT03076580
29 Metabolomic Study of All-age Cardiomyopathy Recruiting NCT03061994
30 Exercise in Genetic Cardiovascular Conditions Recruiting NCT02549664
31 HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy Active, not recruiting NCT01915615

Search NIH Clinical Center for Pulmonary Subvalvular Stenosis

Cochrane evidence based reviews: pulmonary subvalvular stenosis

Genetic Tests for Pulmonary Subvalvular Stenosis

Anatomical Context for Pulmonary Subvalvular Stenosis

MalaCards organs/tissues related to Pulmonary Subvalvular Stenosis:

39
Heart

Publications for Pulmonary Subvalvular Stenosis

Variations for Pulmonary Subvalvular Stenosis

Expression for Pulmonary Subvalvular Stenosis

Search GEO for disease gene expression data for Pulmonary Subvalvular Stenosis.

Pathways for Pulmonary Subvalvular Stenosis

GO Terms for Pulmonary Subvalvular Stenosis

Sources for Pulmonary Subvalvular Stenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....